天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Nogo抗體,Rabbit Monoclonal Nogo Antibody
  • Nogo抗體,Rabbit Monoclonal Nogo Antibody
  • Nogo抗體,Rabbit Monoclonal Nogo Antibody
  • Nogo抗體,Rabbit Monoclonal Nogo Antibody

Nogo抗體;Nogo Antibody—艾普蒂

價(jià)格 詢價(jià)
包裝 20μl 50μl 100μl
最小起訂量 1μl
發(fā)貨地 上海
更新日期 2025-05-29
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:Nogo抗體英文名稱:Rabbit Monoclonal Nogo Antibody
品牌: 艾普蒂產(chǎn)地: 武漢
保存條件: Stored at -20°C for 8225 year. Avoid repeated freeze / thaw cycles.產(chǎn)品類別: 抗體
重組: 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat 宿主: Rabbit
偶聯(lián)物: 靶點(diǎn): Nogo
2025-05-29 Nogo抗體 Rabbit Monoclonal Nogo Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武漢 Stored at -20°C for 8225 year. Avoid repeated freeze / thaw cycles. 抗體

驗(yàn)證與應(yīng)用

應(yīng)用及物種
WB咨詢技術(shù) Human,Mouse,Rat
IF1/20-1/50 Human,Mouse,Rat
IHCIHC:1/100-1/200;IHF:1/50-1/200 Human,Mouse,Rat
ICC1/50-1/200 Human,Mouse,Rat
FCM1/20-1/100 Human,Mouse,Rat
Elisa咨詢技術(shù) Human,Mouse,Rat
   

產(chǎn)品詳情

AliasesASY; Foocen; NI220/250; NOGO; NOGOC; NSP; rat N; RTN X; Rtn4; RTN4-A; RTN4-B1; RTN4-B2; RTN4-C; Vp20;;Nogo
WB Predicted band sizeCalculated MW: 130 kDa ; Observed MW: 40-55 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenA synthesized peptide derived from human Nogo
FormulationPurified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol.

+ +

  •  

     

       Western blot analysis of Nogo expression in HeLa cell lysate.    


  •  

     

       All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    


  •  

     

       All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    


           

參考文獻(xiàn)

以下是3篇關(guān)于Nogo抗體的經(jīng)典文獻(xiàn)概覽(基于公開研究知識(shí)庫整理,非實(shí)時(shí)更新):

---

1. **文獻(xiàn)名稱**: "Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1"

**作者**: Chen MS, Huber AB, van der Haar ME, et al.

**摘要**: 該研究首次發(fā)現(xiàn)Nogo-A是中樞神經(jīng)系統(tǒng)髓鞘中抑制神經(jīng)突生長的關(guān)鍵蛋白,并證明單克隆抗體IN-1可通過中和Nogo-A促進(jìn)脊髓損傷后軸突再生和功能恢復(fù)(發(fā)表于 *Nature*, 2000)。

---

2. **文獻(xiàn)名稱**: "Nogo receptor antagonism promotes stroke recovery by enhanced axonal plasticity"

**作者**: Lee JK, Kim JE, Sivula M, Strittmatter SM.

**摘要**: 研究探討了阻斷Nogo受體(NgR)對(duì)中風(fēng)恢復(fù)的影響,發(fā)現(xiàn)通過抗體或拮抗劑抑制NgR可增強(qiáng)神經(jīng)可塑性和運(yùn)動(dòng)功能恢復(fù),為臨床治療提供了新策略(發(fā)表于 *Journal of Neuroscience*, 2004)。

---

3. **文獻(xiàn)名稱**: "Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons after spinal cord injury in adult primates"

**作者**: Freund P, Schmidlin E, Wannier T, et al.

**摘要**: 在非人靈長類脊髓損傷模型中,抗Nogo-A抗體治療顯著促進(jìn)皮質(zhì)脊髓束軸突發(fā)芽和功能連接重建,驗(yàn)證了其在大型哺乳動(dòng)物中的治療潛力(發(fā)表于 *Nature Medicine*, 2006)。

---

4. **文獻(xiàn)名稱**: "Safety and efficacy of anti-Nogo-A antibody treatment in acute traumatic spinal cord injury: Phase I clinical trial results"

**作者**: Z?rner B, Schwab ME.

**摘要**: 首次針對(duì)抗Nogo-A抗體(ATI355)的I期臨床試驗(yàn),證明其在急性脊髓損傷患者中具有安全性和初步促神經(jīng)修復(fù)活性,為后續(xù)臨床轉(zhuǎn)化奠定基礎(chǔ)(發(fā)表于 *Neurology*, 2010)。

---

**注**:如需具體文獻(xiàn)全文或更新研究,建議通過PubMed或Web of Science檢索DOI獲取詳細(xì)信息。

       

背景信息

Nogo antibodies target Nogo-A, a myelin-associated protein identified as a key inhibitor of axonal regeneration in the central nervous system (CNS). Discovered in the early 2000s, Nogo-A is predominantly expressed by oligodendrocytes and neurons. It belongs to the reticulon family and contains two inhibitory domains: Nogo-66 (extracellular) and Nogo-Δ20 (intracellular). Nogo-A binds to the Nogo-66 receptor (NgR1) and paired immunoglobulin-like receptor B (PirB), activating RhoA/ROCK signaling pathways that collapse growth cones and suppress neurite outgrowth, limiting neural repair after injury.

Research showed that neutralizing Nogo-A with antibodies could enhance axonal sprouting and functional recovery in rodent models of spinal cord injury (SCI) or stroke. Anti-Nogo-A antibodies block its inhibitory signaling, promoting plasticity in corticospinal tracts. This led to preclinical optimism, with some antibodies (e.g., ATI355) advancing to early-phase human trials. However, clinical translation has faced challenges, including variable efficacy, limited regenerative capacity in humans, and potential side effects like pain sensitization.

Despite mixed outcomes, Nogo-A remains a therapeutic target alongside other myelin inhibitors (e.g., MAG, OMgp). Current strategies also explore combining antibodies with rehabilitation or targeting downstream signaling molecules. While Nogo antibodies highlight the CNS’s intrinsic repair barriers, their role in clinical neurorecovery continues to evolve.

       
關(guān)鍵字: Nogo抗體;Nogo;Nogo Antibody;

公司簡介

生物技術(shù)有限公司
成立日期 2024-07-02 (2年) 注冊(cè)資本 20萬人民幣
員工人數(shù) 1-10人 年?duì)I業(yè)額 ¥ 100萬以內(nèi)
主營行業(yè) 抗體,植物生物技術(shù),細(xì)胞培養(yǎng),蛋白組學(xué) 經(jīng)營模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • 上海切爾齊生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注冊(cè)資本:20萬人民幣
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營產(chǎn)品:生物試劑
  • 公司地址:青浦
詢盤

Nogo抗體;Nogo Antibody—艾普蒂相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
¥1200
VIP4年
上海雅吉生物科技有限公司
2025-08-15
¥1280
VIP1年
上海臻科生物科技有限公司
2025-08-15
¥1098
VIP3年
上海滬震實(shí)業(yè)有限公司
2025-08-15
詢價(jià)
湖北艾普蒂生物工程有限公司
2024-02-21
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場變化,或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁 | 企業(yè)會(huì)員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號(hào)  京公海網(wǎng)安備110108000080號(hào)  All rights reserved.